Human RCTPubMed ID: 37385275·2023

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

Garvey WT, Frias JP, Jastreboff AM, et al.

The Lancet, 2023 · n = 938

Key finding

Tirzepatide 15mg produced clinically meaningful weight loss (14.7%) even in the harder-to-treat diabetes population with significant insulin resistance.

Summary

Phase 3 trial in adults with obesity and type 2 diabetes showing tirzepatide 15mg produced 14.7% weight loss and 2.1 percentage point HbA1c reduction.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot

Tirzepatide Preserves Kidney Function in Type 2 Diabetes

American Journal of Kidney Diseases · 2023 · Human RCT